Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Serum protein isoform profiles indicate the progression of hepatitis C virus-induced liver diseases.

Sugimoto K, Shiraki K, Takei Y, Ito M, Nobori T, Suzuki H, Dissanayaka SK, Meno K, Asashima M, Uchida K.

Int J Mol Med. 2013 Apr;31(4):943-50. doi: 10.3892/ijmm.2013.1267. Epub 2013 Feb 4.

PMID:
23381678
2.

The HCV serum proteome: a search for fibrosis protein markers.

Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H.

J Viral Hepat. 2009 Jun;16(6):418-29. doi: 10.1111/j.1365-2893.2009.01083.x. Epub 2009 Feb 15.

PMID:
19226329
3.

SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma.

Schwegler EE, Cazares L, Steel LF, Adam BL, Johnson DA, Semmes OJ, Block TM, Marrero JA, Drake RR.

Hepatology. 2005 Mar;41(3):634-42.

PMID:
15726646
4.

Altered glycosylation, expression of serum haptoglobin and alpha-1-antitrypsin in chronic hepatitis C, hepatitis C induced liver cirrhosis and hepatocellular carcinoma patients.

Mondal G, Saroha A, Bose PP, Chatterjee BP.

Glycoconj J. 2016 Apr;33(2):209-18. doi: 10.1007/s10719-016-9658-2. Epub 2016 Mar 31.

PMID:
27034286
5.

Novel serum biomarker candidates for liver fibrosis in hepatitis C patients.

Gangadharan B, Antrobus R, Dwek RA, Zitzmann N.

Clin Chem. 2007 Oct;53(10):1792-9. Epub 2007 Aug 16.

6.

Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis to cirrhosis.

Costantini S, Capone F, Guerriero E, Maio P, Colonna G, Castello G.

Eur Cytokine Netw. 2010 Dec;21(4):251-6. doi: 10.1684/ecn.2010.0214. Epub 2010 Nov 17.

PMID:
21081303
7.

Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients.

Cedrone A, Covino M, Caturelli E, Pompili M, Lorenzelli G, Villani MR, Valle D, Sperandeo M, Rapaccini GL, Gasbarrini G.

Hepatogastroenterology. 2000 Nov-Dec;47(36):1654-8.

PMID:
11149026
8.

Hepatitis C virus 1b(II) infection and development of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma: a case-control study in Japan.

Tanaka H, Tsukuma H, Yamano H, Okubo Y, Inoue A, Kasahara A, Hayashi N.

J Epidemiol. 1998 Oct;8(4):244-9.

9.

Evaluation of serum percent trisialotransferrin as potential predictive biomarker of hepatocellular dedifferentiation in chronic liver disease.

Gressner OA, Jafari S, Erkens M, Gao C, Stanzel S, Gressner AM.

Clin Chim Acta. 2009 May;403(1-2):188-93. doi: 10.1016/j.cca.2009.02.017. Epub 2009 Mar 10.

PMID:
19281805
10.

A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma.

Steel LF, Shumpert D, Trotter M, Seeholzer SH, Evans AA, London WT, Dwek R, Block TM.

Proteomics. 2003 May;3(5):601-9.

PMID:
12748940
11.

Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.

Ahmed N, Oliva KT, Barker G, Hoffmann P, Reeve S, Smith IA, Quinn MA, Rice GE.

Proteomics. 2005 Nov;5(17):4625-36.

PMID:
16220531
12.

Hepatitis C virus (HCV) genotypes and the influence of HCV subtype 1b on the progression of chronic hepatitis C in Korea: a single center experience.

Cho EJ, Jeong SH, Han BH, Lee SU, Yun BC, Park ET.

Clin Mol Hepatol. 2012 Jun;18(2):219-24. doi: 10.3350/cmh.2012.18.2.219. Epub 2012 Jun 26.

13.

Measurement of human intercellular adhesion molecule 1 in the blood is useful for predicting the occurrence of hepatocellular carcinomas from chronic hepatitis C and liver cirrhosis.

Moriyama M, Matsumura H, Shioda J, Aoki H, Nakamura H, Arakawa Y, Nirei K, Yamagami H, Kaneko M, Tanaka N, Arakawa Y.

Intervirology. 2006;49(6):327-38. Epub 2006 Aug 21.

PMID:
16926545
14.

Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry.

Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Yu CY, Lu FJ, Chow LP.

J Proteome Res. 2005 Nov-Dec;4(6):2062-9.

PMID:
16335951
15.

Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan.

Chen DS.

Princess Takamatsu Symp. 1995;25:27-32. Review.

PMID:
8875606
16.

The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma.

Kanmura S, Uto H, Sato Y, Kumagai K, Sasaki F, Moriuchi A, Oketani M, Ido A, Nagata K, Hayashi K, Stuver SO, Tsubouchi H.

J Gastroenterol. 2010 Apr;45(4):459-67. doi: 10.1007/s00535-009-0160-5. Epub 2009 Dec 9.

PMID:
20012107
17.

Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification.

Cui J, Kang X, Dai Z, Huang C, Zhou H, Guo K, Li Y, Zhang Y, Sun R, Chen J, Li Y, Tang Z, Uemura T, Liu Y.

J Cancer Res Clin Oncol. 2007 Nov;133(11):825-34. Epub 2007 May 22.

PMID:
17516088
18.

Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach.

Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Chen DS, Yu CY, Wen CL, Lu FJ, Chow LP.

Proteomics. 2006 May;6(9):2865-73.

PMID:
16586433
19.

Circulating and hepatic Fas expression in HCV-induced chronic liver disease and hepatocellular carcinoma.

El Bassiouny AE, El-Bassiouni NE, Nosseir MM, Zoheiry MM, El-Ahwany EG, Salah F, Omran ZS, Ibrahim RA.

Medscape J Med. 2008 Jun 3;10(6):130.

20.

High serum alanine aminotransferase levels for the first three successive years can predict very high incidence of hepatocellular carcinoma in patients with Child Stage A HCV-associated liver cirrhosis.

Miyakawa K, Tarao K, Ohshige K, Morinaga S, Ohkawa S, Okamoto N, Shibuya A, Adachi S, Miura Y, Fujiyama S, Miyase S, Tomita K.

Scand J Gastroenterol. 2009;44(11):1340-8. doi: 10.3109/00365520903222681.

PMID:
19891585
Items per page

Supplemental Content

Write to the Help Desk